Majedie Asset Management Ltd purchased a new stake in shares of Pfizer, Inc. (NYSE:PFE) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 312,460 shares of the biopharmaceutical company’s stock, valued at approximately $10,689,000. Pfizer comprises approximately 1.1% of Majedie Asset Management Ltd’s portfolio, making the stock its 23rd largest position.

A number of other hedge funds have also recently bought and sold shares of the stock. Asset Planning Services Ltd. increased its stake in Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares during the last quarter. Orrstown Financial Services Inc. increased its stake in Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares during the last quarter. Cable Hill Partners LLC increased its stake in Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 265 shares during the last quarter. D Orazio & Associates Inc. increased its stake in Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 28 shares during the last quarter. Finally, Acropolis Investment Management LLC increased its stake in Pfizer by 1.9% in the first quarter. Acropolis Investment Management LLC now owns 5,251 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 100 shares during the last quarter. Institutional investors and hedge funds own 70.10% of the company’s stock.

Pfizer, Inc. (PFE) opened at 33.31 on Tuesday. The company has a 50-day moving average price of $33.38 and a 200 day moving average price of $33.25. Pfizer, Inc. has a 12 month low of $29.83 and a 12 month high of $35.53. The stock has a market capitalization of $198.79 billion, a price-to-earnings ratio of 24.37 and a beta of 1.00.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.11% and a net margin of 15.84%. The firm had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same period in the previous year, the firm posted $0.64 EPS. The company’s quarterly revenue was down 1.9% compared to the same quarter last year. Equities analysts predict that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a yield of 3.84%. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.

ILLEGAL ACTIVITY NOTICE: “Majedie Asset Management Ltd Invests $10.69 Million in Pfizer, Inc. (PFE)” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/08/08/majedie-asset-management-ltd-invests-10-69-million-in-pfizer-inc-pfe.html.

PFE has been the topic of a number of recent research reports. Citigroup Inc. downgraded Pfizer from a “neutral” rating to a “sell” rating and lowered their target price for the stock from $38.00 to $31.00 in a research note on Tuesday, May 16th. BidaskClub upgraded Pfizer from a “strong sell” rating to a “sell” rating in a research note on Saturday. Jefferies Group LLC set a $35.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. BMO Capital Markets upgraded Pfizer from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $33.00 to $37.00 in a research note on Wednesday, August 2nd. Finally, Barclays PLC restated a “buy” rating and issued a $38.00 target price on shares of Pfizer in a research note on Wednesday, May 3rd. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the company. Pfizer presently has an average rating of “Hold” and an average price target of $37.77.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.